Common use of Common Interest Clause in Contracts

Common Interest. All information exchanged between the Parties regarding the prosecution, maintenance, enforcement and defense of Patents under this ARTICLE 7 will be deemed to be Confidential Information of the disclosing Party. In addition, the Parties acknowledge and agree that, with regard to such prosecution, maintenance, enforcement and defense, the interests of the Parties as collaborators, licensors and/or licensees are, for their mutual benefit, to obtain patent protection and plan patent defense against potential patentability/invalidity challenges or infringement activities by Third Parties, and as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning Patents under this ARTICLE 7, including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything to the contrary in this Agreement, to the extent a Party has a good faith belief that any information required to be disclosed by such Party to the other Party under this ARTICLE 7 is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party shall not be required to disclose such information and the Parties shall in good faith cooperate to agree upon a procedure (which may include entering into a specific common interest agreement, disclosing such information on a “for counsel eyes only” basis or similar procedure) under which such information may be disclosed without waiving or breaching such privilege or immunity.

Appears in 2 contracts

Samples: Collaboration and License Agreement (Caribou Biosciences, Inc.), Collaboration and License Agreement (Caribou Biosciences, Inc.)

AutoNDA by SimpleDocs

Common Interest. All information exchanged between the Parties regarding the prosecutionProsecution and Maintenance, maintenance, and enforcement and defense defense, of Patents the Patent Rights under this ARTICLE 7 Article 10 (Intellectual Property) will be deemed to be Confidential Information of the disclosing Party. In addition, the Parties acknowledge and agree that, with regard to such prosecutionProsecution and Maintenance, maintenance, and enforcement and defensedefense of the Patent Rights under this Article 10 (Intellectual Property), the interests of the Parties as collaborators, licensors and/or licensees are, for their mutual benefit, collaborators and licensor and licensee are to obtain the strongest patent protection and plan patent defense against potential patentability/invalidity challenges or infringement activities by Third Partiespossible, and as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning Patents the Patent Rights under this ARTICLE 7Article 10 (Intellectual Property), including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything to the contrary in this Agreementcontained herein, to the extent a Party has a good faith belief that any information required to be disclosed by such Party to the other Party under this ARTICLE 7 Article 10 (Intellectual Property) is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party shall will not be required to disclose such information and the Parties shall will in good faith cooperate to agree upon a procedure (which may include including entering into a specific common interest agreement, disclosing such information on a “for counsel eyes only” basis or similar procedure) under which such information may be disclosed without waiving or breaching such privilege or immunity.

Appears in 2 contracts

Samples: Collaboration and License Agreement (Metagenomi Technologies, LLC), Collaboration and License Agreement (Ionis Pharmaceuticals Inc)

Common Interest. All information exchanged between the Parties regarding the prosecutionProsecution and Maintenance, maintenancedefense, enforcement and defense enforcement, of Patents the Patent Rights under this ARTICLE 7 Article 13 (Intellectual Property) will be deemed to be Confidential Information of the disclosing Party. In addition, the Parties acknowledge and agree that, with regard to such prosecutionProsecution and Maintenance, maintenancedefense, and enforcement and defenseof the Patent Rights under this Article 13 (Intellectual Property), the interests of the Parties as collaborators, licensors and/or licensees are, for their mutual benefit, licensor and licensee are to obtain the strongest patent protection and plan patent defense against potential patentability/invalidity challenges or infringement activities by Third Partiespossible, and as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning Patents the Patent Rights under this ARTICLE 7Article 13 (Intellectual Property), including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything any provision to the contrary in this Agreementcontained herein, to the extent a Party has a good faith belief that any information required to be disclosed by such Party to the other Party under this ARTICLE 7 Article 13 (Intellectual Property) is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party shall will not be required to disclose such information and the Parties shall will in good faith cooperate to agree upon a procedure (which may include including entering into a specific common interest agreement, disclosing such information on a “for counsel eyes only” basis or similar procedure) under which such information may be disclosed without waiving or breaching such privilege or immunity.

Appears in 1 contract

Samples: Exclusive License Agreement (Neurocrine Biosciences Inc)

Common Interest. All information Information exchanged between the Parties regarding the prosecution, maintenance, enforcement and defense of Patents under this ARTICLE 7 Article 11 will be deemed to be Confidential Information of the disclosing Party. In addition, the Parties acknowledge and agree that, with regard to such prosecution, maintenance, enforcement and defense, the interests of the Parties as collaborators, licensors and/or or licensees areare to, for their mutual benefit, to obtain patent protection and plan patent defense against potential patentability/invalidity challenges or infringement activities by Third Parties, and as such, are aligned and are legal in nature. The Parties agree Each Party agrees and acknowledge acknowledges that they have it has not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning Patents under this ARTICLE 7Article 11, including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything to the contrary in this Agreement, to the extent a Party has a good faith belief that any information Information required to be disclosed by such Party to the other Party under this ARTICLE 7 Article 11 is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party shall not be required to disclose such information Information and the Parties shall in good faith cooperate to agree upon a procedure (which may include entering into a specific common interest agreement, disclosing such information Information on a “for counsel eyes only” basis or similar procedure) under which such information Information may be disclosed without waiving or breaching such privilege or immunity.

Appears in 1 contract

Samples: License and Collaboration Agreement (I-Mab)

Common Interest. All information exchanged between the Parties regarding the prosecution, maintenance, enforcement enforcement, and defense of Patents Patent Rights or a Patent Challenge with respect to a Third Party’s Patent Rights under this ARTICLE 7 Article 10 (Intellectual Property) will be deemed to be the Confidential Information of the disclosing Party. In addition, the Parties acknowledge stipulate and agree that, with regard to such prosecution, maintenance, enforcement enforcement, and defense, defense the interests of the Parties as collaborators, licensors and/or licensees are, for their mutual benefit, collaborators and licensor and licensee are to obtain the strongest patent protection and plan patent defense against potential patentability/invalidity challenges or infringement activities by Third Partiespossible, and as such, are aligned and are legal in nature. The Parties stipulate and agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning Patents the Patent Rights under this ARTICLE 7Article 10 (Intellectual Property), including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything any provision to the contrary set forth in this Agreement, to the extent a Party has a good faith belief that any information required to be disclosed by such Party to the other Party under this ARTICLE 7 Article 10 (Intellectual Property) is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party shall will not be required to disclose such information and the Parties shall will in good faith cooperate to agree upon a procedure (which may include including entering into a specific common interest agreement, disclosing such information on a “for counsel eyes only” basis or similar procedure) under which such information may be disclosed without waiving or breaching such privilege or immunity.

Appears in 1 contract

Samples: , and Option Agreement (Sarepta Therapeutics, Inc.)

AutoNDA by SimpleDocs

Common Interest. All information exchanged between the Parties regarding the prosecutionProsecution and Maintenance, maintenance, and enforcement and defense defense, of Patents under this ARTICLE 7 Article 9 (Intellectual Property; Ownership) will be deemed to be Confidential Information of the disclosing Party. In addition, the Parties acknowledge and agree that, with regard to such prosecutionProsecution and Maintenance, maintenance, and enforcement and defense, the interests of the Parties as collaborators, licensors and/or licensees are, for their mutual benefit, collaborators and licensor and licensee are to obtain the strongest patent protection and plan patent defense against potential patentability/invalidity challenges or infringement activities by Third Partiespossible, and as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the Patents under this ARTICLE 7Article 9 (Intellectual Property; Ownership), including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything to the contrary in this Agreementcontained herein, to the extent a Party has a good faith belief that any information required to be disclosed by such Party to the other Party under this ARTICLE 7 Article 9 (Intellectual Property; Ownership) is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party shall not be required to disclose such information and the Parties shall in good faith cooperate to agree upon a procedure (which may include including entering into a specific common interest agreement, disclosing such information on a “for counsel eyes only” basis or similar procedure) under which such information may be disclosed without waiving or breaching such privilege or immunity.

Appears in 1 contract

Samples: License and Collaboration Agreement (CG Oncology, Inc.)

Common Interest. All information exchanged between the Parties regarding the prosecution, maintenance, enforcement and defense of Patents under this ARTICLE 7 8 will be deemed to be Confidential Information of the disclosing Party. In addition, the Parties acknowledge and agree that, with regard to such prosecution, maintenance, enforcement and defense, the interests of the Parties as collaborators, licensors and/or licensees arecollaborators and Harpoon and licensee are to, for their mutual benefit, to obtain patent protection and plan patent defense against potential patentability/invalidity challenges or infringement activities by Third Parties, and as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning Patents under this ARTICLE 78, including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything to the contrary in this Agreement, to the extent a Party has a good faith belief that any information required to be disclosed by such Party to the other Party under this ARTICLE 7 8 is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party shall not be required to disclose such information and the Parties shall in good faith cooperate to agree upon a procedure (which may include entering into a specific common interest agreement, disclosing such information on a “for counsel eyes only” basis or similar procedure) under which such information may be disclosed without waiving or breaching such privilege or immunity.

Appears in 1 contract

Samples: Discovery Collaboration and License Agreement (Harpoon Therapeutics, Inc.)

Time is Money Join Law Insider Premium to draft better contracts faster.